PHARMANIAGA MEFENAMIC TABLET 500MG

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

MEFENAMIC ACID

Boleh didapati daripada:

PHARMANIAGA MANUFACTURING BERHAD

INN (Nama Antarabangsa):

MEFENAMIC ACID

Unit dalam pakej:

250 Tablets; 100 Tablets; 1000Tablet Tablets; 500 Tablets

Dikeluarkan oleh:

PHARMANIAGA MANUFACTURING BERHAD

Risalah maklumat

PHARMANIAGA MEFENAMIC TABLET /
CAPSULE
Mefenamic Acid (250mg,500mg)
1
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_
WHAT IS IN THIS LEAFLET
1.
What PHARMANIAGA
MEFENAMIC is used for
2.
How PHARMANIAGA
MEFENAMIC works
3.
Before you use
PHARMANIAGA
MEFENAMIC
4.
How to use PHARMANIAGA
MEFENAMIC
5.
While you are using it
6.
Side effects
7.
Storage and Disposal of
PHARMANIAGA
MEFENAMIC
8.
Product Description
9.
Manufacturer and Product
Registration Holder
10.
Date of revision
WHAT
PHARMANIAGA
MEFENAMIC IS USED FOR
PHARMANIAGA
MEFENAMIC
contains mefenamic acid. It is used
for the relief of mild to moderate
pain including headache, toothache,
pain following an operation or after
childbirth and period pain. It is also
used for muscle and joint pain such
as
rheumatoid
arthritis
and
osteoarthritis. It can also be used to
treat excessively heavy periods.
HOW
PHARMANIAGA
MEFENAMIC WORKS
PHARMANIAGA
MEFENAMIC
belongs to a group of medicines
called
non-steroidal
anti-
inflammatory
drugs
(NSAIDs).
These medicines reduce pain and
inflammation
by
blocking
the
production of a chemical produced
by the body called prostaglandins.
BEFORE YOU USE PHARMANIAGA
MEFENAMIC
_-When you must not use it _
Do
not
take
PHARMANIAGA
MEFENAMIC if:
•
You
are
allergic
to
mefenamic
acid
or
any
of
the
other
ingredients
in
the
tablet
or
capsule.
•
You have had an allergy to aspirin
or other NSAIDs.
•
You
currently
have
a
stomach
ulcer or suffer from inflammatory
bowel disease.
•
You have severe problems with
your kidneys, liver or heart.
•
You previously having diarrhea
on taking this medicine.
•
You
are
breast
feeding
or
pregnant.
Do
not
give
PHARMANIAGA
MEFENAMIC
children
under
14
years of age.
Do
not
take
PHARMANIAGA
MEFENAMIC if any of the above
applies to you. If you are not sure,
talk to your doctor or pharmacist
before
taking
PHARMANIAGA
MEFENAMIC.
_ _
_-Before you start to use it _
Before you take PHARMANIAGA
MEFENAMIC,
your
doctor
or
pharmacist needs to know if you
have
or
have
had
any
of
the
following conditions:
•
Ulcer
or
s

Ciri produk

MEFENA
ablet
®
apsule
C
T
MIC
Mefenamic Tablet Capsule Leaflet Size: 297 mm (W) x 210 mm (H)
Version 23
Date: 17-09-2020
DESCRIPTION
_PHARMANIAGA MEFENAMIC TABLET 250 MG._
A yellow, round, biconvex film-coated tablet with a breakline on
one side and plain on the other.
_PHARMANIAGA MEFENAMIC TABLET 500 MG._
A yellow, oblong, film-coated tablet with Pharmaniaga icon on
one side and scoreline on the other.
_PHARMANIAGA MEFENAMIC CAPSULE 250 MG._
Opaque ivory/light blue, size 1, hard gelatin capsule with
Pharmaniaga icon and '250' markings.
COMPOSITION
Each film-coated tablet contains Mefenamic acid 250 mg or 500
mg.
Each capsule contains Mefenamic acid 250 mg.
PHARMACODYNAMICS
Mefenamic acid has analgesic, anti-inflammatory and anti-py-
retic properties. It is an inhibitor of cyclo-oxygenase, resulting in
decreased
formation
of
precursors
of
prostaglandins
and
thromboxanes from arachidonic acid. Also Mefenamic acid has
been shown to inhibit competitively the actions of prostaglan-
dins.
PHARMACOKINETICS
ABSORPTION
Mefenamic acid is rapidly absorbed after oral administration
from the gastrointestinal tract. Following administration of a one
gram oral dose to adults, peak plasma levels of 10 µg/mL occur
in 1 to 4 hours, with a half-life of 2 hours. Plasma levels are
proportional to dose, following multiple doses, with no drug
accumulation. One gram of mefenamic acid administered four
times daily produces peak blood levels of 20 µg/mL by the
second
day
of
administration.
Concomitant
ingestion
of
antacids containing magnesium hydroxide has been shown to
significantly increase the rate and extent of mefenamic acid
absorption.
DISTRIBUTION
Mefenamic acid is extensively bound to plasma proteins.
METABOLISM
Mefenamic acid metabolism is predominantly mediated via
cytochrome P450 (CYP) 2C9 in the liver. Patients who are
known or suspected to be poor CYP 2C9 metabolizers based
on previous history/experience with other CYP 2C9 substrates
should be administered mefenamic acid with caution as they
may have abnormally high pla